Study Title
A study on the effectiveness of low-dose olanzapine in preventing nausea and vomiting during chemotherapy
Objective
To evaluate the effectiveness of 5 mg olanzapine in preventing chemotherapy-induced nausea and vomiting (CINV) in female patients with gastrointestinal tract tumors undergoing moderately emetogenic chemotherapy (MEC).
Methods
Patients received either 5 mg olanzapine with palonosetron and dexamethasone or a standard two-drug combination of dexamethasone and palonosetron. The study assessed total protection rates, total control rates, complete remission rates, and quality of life, as well as collected adverse events data.
Results
1) The olanzapine group showed higher total protection rates compared to the control group in both the entire age group and the subgroup aged 60 years and above. 2) The olanzapine group exhibited superior acute phase protection rates in both age brackets compared to the control group. Quality of life was also better in the olanzapine group, with improved appetite and higher incidence of drowsiness.
Conclusion
Olanzapine can improve CINV induced by MEC regimen in female patients of all age groups, including the elderly, and enhance their quality of life.
Clinical Trial Registration
Clinical Trial Registration, identifier: ChiCTR20000368269, 25/08/2020
Practical Solutions and Value
Clinical trials are crucial for developing safe treatments. Our AI-driven platform, DocSym, consolidates clinical standards and research for easy access. Streamlining operations is essential in healthcare, and our mobile apps support scheduling, monitoring treatments, and telemedicine, enhancing patient care and expanding services digitally. AI can improve workflows and patient outcomes, reducing paper routines. Learn more at aidevmd.com.
